Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection.

Publication/Presentation Date

8-31-2022

Abstract

The renin-angiotensin-aldosterone system is a neurohormonal system responsible for maintaining homeostasis of fluid regulation, sodium balance, and blood pressure. The complexity of this pathway enables it to be a common target for blood pressure and volume-regulating medications. The mineralocorticoid receptor is one of these targets, and is found not only in the kidney, but also tissues making up the heart, blood vessels, and adipose. Mineralocorticoid receptor antagonists have been shown to slow progression of chronic kidney disease, treat refractory hypertension and primary aldosteronism, and improve morbidity and mortality in management of heart failure with reduced ejection fraction. The more well-studied medications were derived from steroid-based compounds, and thus come with a distinct side-effect profile. To avoid these adverse effects, developing a mineralocorticoid receptor antagonist (MRA) from a non-steroidal base compound has gained much interest. This review will focus on the novel non-steroidal MRA, Finerenone, to describe its unique mechanism of action while summarizing the available clinical trials supporting its use in patients with various etiologies of cardiorenal disease.

First Page

101386

Last Page

101386

ISSN

1535-6280

Disciplines

Medicine and Health Sciences

PubMedID

36057315

Department(s)

Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, Fellows and Residents

Document Type

Article

Link to Full Text

Share

COinS